PSNL (Personalis, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PSNL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-15 | Richard Chen | President and CMO | MIXED | — | — |
| 2026-07-09 | Christopher M Hall | Chief Executive Officer | MIXED | — | — |
| 2026-06-29 | Aaron Tachibana | CFO AND COO | MIXED | — | — |
| 2026-06-26 | Christopher M Hall | Chief Executive Officer | MIXED | — | — |
| 2026-06-26 | Aaron Tachibana | CFO AND COO | MIXED | — | — |
| 2026-06-11 | KARIN EASTHAM | Director | A | — | — |
| 2026-06-05 | Aaron Tachibana | CFO AND COO | MIXED | — | — |
| 2026-05-29 | Christopher M Hall | Chief Executive Officer | MIXED | — | — |
| 2026-05-29 | Aaron Tachibana | CFO AND COO | MIXED | — | — |
| 2026-05-14 | Lonnie Shoff | Director | A | — | — |
| 2026-05-14 | A BLAINE BOWMAN | Director | A | — | — |
| 2026-05-14 | WOODROW A MYERS JR | Director | A | — | — |
| 2026-05-14 | Olivia Kyusuk Bloom | Director | A | — | — |
| 2026-05-14 | KARIN EASTHAM | Director | A | — | — |
| 2026-05-14 | KENNETH J WIDDER | Director | A | — | — |
| 2026-03-17 | Stephen Michael Moore | SVP and Chief Legal Officer | A | — | — |
| 2026-03-17 | Christopher M Hall | Chief Executive Officer | A | — | — |
| 2026-03-17 | Aaron Tachibana | CFO AND COO | A | — | — |
| 2026-03-17 | Richard Chen | President and CMO | A | — | — |
| 2026-02-25 | Aaron Tachibana | CFO AND COO | A | — | — |
| 2026-02-25 | Stephen Michael Moore | SVP and Chief Legal Officer | A | — | — |
| 2026-02-25 | Richard Chen | CHIEF MEDICAL OFFICER AND EVP | A | — | — |
| 2026-02-25 | Christopher M Hall | PRESIDENT AND CEO | A | — | — |
| 2026-02-13 | Tempus AI, Inc. | 10%+ Owner | Buy | — | — |
| 2026-01-23 | Aaron Tachibana | CFO AND COO | MIXED | — | — |
| 2025-11-28 | Aaron Tachibana | CFO AND COO | MIXED | — | — |
| 2025-11-05 | Christopher M Hall | PRESIDENT AND CEO | Sell | — | — |
| 2025-07-30 | Aaron Tachibana | CFO AND COO | Sell | — | — |
| 2025-07-30 | Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sell | — | — |
| 2025-05-20 | Olivia Kyusuk Bloom | Director | A | — | — |
| 2025-05-20 | Aaron Tachibana | CFO AND COO | Sell | — | — |
| 2025-05-20 | WOODROW A MYERS JR | Director | A | — | — |
| 2025-05-20 | Lonnie Shoff | Director | A | — | — |
| 2025-05-20 | A BLAINE BOWMAN | Director | A | — | — |
| 2025-05-20 | KENNETH J WIDDER | Director | A | — | — |
| 2025-05-20 | Stephen Michael Moore | SVP and Chief Legal Officer | Sell | — | — |
| 2025-05-20 | Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sell | — | — |
| 2025-05-20 | KARIN EASTHAM | Director | A | — | — |
| 2025-03-18 | Aaron Tachibana | CFO AND COO | A | — | — |
| 2025-03-18 | Richard Chen | CHIEF MEDICAL OFFICER AND EVP | A | — | — |
| 2025-03-18 | Christopher M Hall | PRESIDENT AND CEO | A | — | — |
| 2025-03-18 | Stephen Michael Moore | SVP and Chief Legal Officer | A | — | — |
| 2025-01-30 | Aaron Tachibana | CFO AND COO | Sell | — | — |
| 2025-01-30 | Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sell | — | — |
| 2024-12-18 | Aaron Tachibana | CFO AND COO | Sell | — | — |
| 2024-12-18 | Stephen Michael Moore | SVP and Chief Legal Officer | Sell | — | — |
| 2024-12-18 | Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sell | — | — |
| 2024-11-20 | Aaron Tachibana | CFO AND COO | Sell | — | — |
| 2024-11-20 | Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sell | — | — |
| 2024-11-20 | Stephen Michael Moore | SVP and Chief Legal Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 12,843,022 | — |
| — | — | 4,122,518 | — |
| — | 10%+ Owner | 3,753,340 | — |
| — | 10%+ Owner | 2,458,209 | — |
| — | — | 1,958,726 | — |
| — | 10%+ Owner | 1,958,726 | — |
| — | President and CEO | 622,444 | — |
| — | Chief Executive Officer | 235,986 | — |
| — | CFO AND COO | 198,833 | — |
| — | President and CMO | 173,880 | — |
| — | Director | 113,506 | — |
| — | SVP and Chief Legal Officer | 92,325 | — |
| — | Director | 37,190 | — |
| — | Director | 32,366 | — |
| — | Director | 27,265 | — |
| — | Director | 20,000 | — |
| — | Director | 19,756 | — |
| — | Director | 19,756 | — |
| — | Director | 13,506 | — |
| — | Chief Business Officer | 11,000 | — |
| — | Director | 6,250 | — |
| — | Director | 2,736 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PSNL quote page; the site-wide leaderboard is on the insider transactions hub.